Disappointingly, an open label trial of Abatacept in 16 PBC patients who had not responded to UDCA therapy reported that only a single patient met the primary endpoint of a reduction in ALP of over 40% from baseline and there were no significant reductions in serum IgM (159). The gene discussed is CD40LG; the disease is primary biliary cholangitis.